Compare Jumia Technologies AG - ADR (JMIA) vs Merck & Co., Inc. (MRK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Jumia Technologies AG - ADR vs Merck & Co., Inc. — how do they compare? Jumia Technologies AG - ADR trades at $6.26 (market cap $783.99M), while Merck & Co., Inc. trades at $125.7 (market cap $307.25B). The key difference: Merck & Co., Inc. is far larger — about 391.9× Jumia Technologies AG - ADR's market cap, and Merck & Co., Inc. pays a 2.73% dividend while Jumia Technologies AG - ADR pays none. Which is the better fit depends on your goals.
| JMIA | MRK | |
|---|---|---|
Market Cap | $783.99M | $307.25B |
Sector | Consumer Cyclical | Health |
52-Week High | $14.60 | $129.52 |
52-Week Low | $4.45 | $77.60 |
Enterprise Value | $731.09M | $350.66B |
Dividend Yield | — | 2.73% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
JMIA trades at $6.36, down 2.15% today, with a bearish technical signal from moving averages. The company shows improving fundamentals with revenue growth to $188.93M in 2025 and narrowing losses, targeting 2027 profitability. Analyst sentiment remains positive with 71% buy ratings despite recent earnings misses. Recent news highlights strong Q1 2026 performance and strategic board appointments.
JMIA presents a high-risk opportunity with significant upside potential if profitability targets are met. The stock faces execution risks in African e-commerce expansion and persistent negative cash flow, but strong revenue growth and analyst support suggest potential for recovery if the 2027 breakeven timeline is achieved.
Merck (MRK) trades at $125.44, down 1.62% on the day, with a neutral technical signal. The company reported strong 2025 results with revenue of $65.01B and net income of $18.25B, though Q1 2026 saw a loss. Recent news highlights Merck's acquisition of Terns Pharmaceuticals to bolster its oncology pipeline, with institutional investors increasing positions. Valuation ratios include a P/E of 35.04 and ROE of 18.97%, indicating solid profitability but premium pricing.
Outlook remains positive with a consensus price target of $137.30, reflecting 9.5% upside potential. Risks include rising debt levels and competitive pressures in pharma. Analyst sentiment is bullish with 68% buy ratings, supporting a favorable investment case amid ongoing strategic acquisitions.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Jumia Technologies AG - ADR
Jumia Technologies AG is the pan-African e-commerce platform. The company's platform consists of a marketplace, which connects sellers with consumers. Its logistics service enables the shipment and delivery of packages from sellers to consumers, and the company's payment service facilitates transactions among participants active on its platform in selected markets. Jumia generates revenue from Sales of goods, Commissions, Fulfillment, Value-added services, and Marketing & Advertising. Its geographical segments are West Africa, North Africa, East & South Africa, Europe, and United Arab Emirates. The firm generates most of its revenue from the West Africa segment.
Read more on JMIA →About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →
